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1. INTRODUCTION 
 
This research is devoted to the study of KCNQ channels in vascular smooth muscle cells 
(VSMCs) of small arteries of the rat. In particular, we investigated the effects of new substances 
which are expected to work as KCNQ channels openers. 
 
1.1. Basis for this investigation 
 
KCNQ channels were widely studied in the nervous system because regulation of their 
activity is important for many neurological disorders. Based on these investigations new 
medications were discovered representing pharmacological modulators of KCNQ channels. 
In the last years it was revealed that KCNQ channels are also present in some smooth 
muscle cells where they take part in contraction. The presence of KCNQ channels in vascular 
smooth muscle cells (VSMCs) is especially important. Theoretically, regulation of the activity of 
KCNQ channels gives the possibility to regulate the contractility of VSMCs that in turn is 
connected with vascular tone. The connection between KCNQ channels and vascular tone was 
confirmed by a few newer studies. In 2007 it was discovered that the hormone vasopressin leads 
to vasoconstriction by inhibition of KCNQ5 channels in VSMCs (Brueggemann et al., 2007). 
Another example showed that baroreceptors of the aortic arch express KCNQ channels which 
regulate the sensitivity of the mechanosensitive neurons to changes in arterial blood pressure 
(Wladyka et al., 2008). 
Thus, investigations of vascular reactions with participation of KCNQ channels are 
necessary for a more exact understanding of the processes of vascular tone regulation. In 
addition, such studies may help to develop new medications for cardiovascular diseases. 
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1.2. Basic features of vessel physiology 
 
All arteries have in principle the same structure. The arterial vascular wall consists of 
three layers: the outer tunica adventitia, a central tunica media, and the inner tunica intima. 
Depending on the amount of muscular and elastic components in the tunica media all arteries are 
divided into 3 types: elastic, muscular and mixed arteries. Small arteries belong to the muscular 
type (fig. 1.1).   
 
 
Figure 1.1 Structure of a small artery: A - tunica intima, B - internal elastic lamina, C - tunica 
media, D - external elastic lamina, E - tunica adventitia. 
 
In small arteries, the force of the pulse-wave essentially decreases because of remoteness 
from the heart. However, these vessels possess a considerable muscular component in the tunica 
media in order to facilitate blood flow regulation. The diameter of these arteries can decrease 
during constriction and increase during relaxation of VSMCs. The thickness of the wall of these 
arteries essentially exceeds the diameter of the aperture. Such vessels create a resistance for the 
streaming blood. Therefore they are often called “resistive”. 
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Intima 
The tunica intima is a comparatively thin layer which consists of one layer of endothelial 
cells and the internal elastic lamina. The internal elastic lamina represents one layer of elastic 
fibers. This lamina supports the endothelial cells which are in direct contact with the blood flow. 
Endothelial cells, along with other factors, play important roles in vessel relaxation and 
contraction (Furchgott et al., 1989).  
Endothelium-dependent relaxation occurs because of three different endothelium-derived 
relaxing factors (EDRFs): nitric oxide – NO (Ignarro et al., 1987), prostacyclin – PGI2 (Bunting 
et al., 1976), and an unidentified endothelium-derived hyperpolarizing factor – EDHF (Feletou et 
al., 1988; Chen et al., 1988). EDRFs are released by a large number of agents (e.g., 
acetylcholine, ATP and ADP, substance P, bradykinin, histamine, thrombin, serotonin) and by 
shear stress. Endothelium-dependent relaxation occurs in resistance vessels as well as in larger 
arteries. 
There is also endothelium-dependent vasoconstriction produced by a few endothelium-
derived contracting factors (EDCFs) such as Endothelin-1 – ET-1 (Yanagisawa et al., 1988), 
Angiotensin II – Ang II (Hernandez Schulman et al., 2007), Thromboxane A2 – TXA2 (Oates et 
al., 1988) and prostaglandin H2 –  PGH2 (Davidge, 2001). 
 
Media 
The tunica media of small arteries consists of smooth muscle cells and elastic fibers 
located spirally. The spiral arrangement of the VSMCs promotes greater reduction of the vessel 
aperture. The tunica media borders on the internal elastic lamina at the luminal side, but there is 
no elastic lamina within the media (Carlson et al., 1982; Lee et al., 1983a). The volume fraction 
occupied by VSMCs in small arteries is greater than in larger vessels (Todd et al., 1983). The 
number of VSMCs in small arteries depends on vessel diameter: from approximately six layers 
in 300-µm vessels (Lee et al., 1983b) to one cell layer in 30- to 50-µm arterioles (Gattone et al., 
1986, Miller et al., 1987, Walmsley et al., 1982).  
 
  
 
- 8 - 
Adventitia 
The tunica adventitia of small arteries consists of connective tissue (elastin and collagen), 
fibroblasts, mast cells, macrophages and Schwann cells with associated nerve axons (Laher et al., 
1986; Rhodin, 1980). In small arteries, nerves do not penetrate the media (Griffith et al., 1982; 
Luff et al.1987; Owen et al., 1983, Rhodin, 1980). The volume fraction of nerves in the 
adventitia depends on vessel location: from 1% in proximal small arteries to 3% in the more 
distal small arteries (Lee et al., 1983a; Nilsson et al., 1986; Smeda et al., 1988). Nerve endings 
have a great influence on vascular function.  
 
Vessel contraction 
Contraction of small arteries, as in large arteries (Deth et al., 1974), is dependent on the 
presence (Mulvany et al., 1980) and influx (Cauvin et al., 1984) of extracellular calcium. 
Calcium gets into the VSMC trough potential-dependent calcium channels (electromechanical 
coupling), receptor- or store-activated calcium permeating channels (pharmacomechanical 
coupling) and from the sarcoplasmic reticulum. 
Pharmacomechanical coupling is a major mechanism of VSMC contraction. This kind of 
contraction or dilatation could be caused by such substances as catecholamines (phenylephrine), 
histamine, acetylcholine, serotonin, angiotensin, nitric oxide (NO), carbon dioxide (CO2), K
+ 
and 
H
+
 ions, and prostaglandins (tromboxane, U46619). Some of these substances were used in the 
present study as vessel preconstrictors in the myograph experiments. 
The diameter of small vessels depends on different factors released from nerve endings or 
surrounding tissues and transported by the blood flow (hormones). In addition, there are 
mechanical factors like shear stress and transmural pressure as well as influences from proximal 
and distal vessel segments.  
That’s why the investigation of vessel contractility mechanisms is not easy. For example, 
at studying VSMC-based mechanisms the endothelium should be removed, the action of 
sympathetic nerve endings be blocked, and resting tension selected according to the vessel 
location, e.g. 100 mmHg for Gracilis and 15 mmHg for Intrapulmonary arteries (Steeds et al., 
1997; Chou et al., 2002). 
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1.3. KCNQ channels 
 
KCNQ channels (also known as Kv7 channels) are a small family of voltage-activated 
potassium channels.  
 
1.3.1. Potassium channels 
All cells are surrounded by a lipid membrane which works as a barrier to the diffusion of 
many substances, including ions. Transporting necessary ions through the membrane is possible 
due to proteinaceous channels integrated into the membranes. Ions cross the membrane when 
these channels are open. Potassium channels (K
+ 
channels) are a subset of membrane channels 
selective for potassium ions (K
+
).  
The concentration of K
+
 ions is usually approximately 25-times higher inside then 
outside the cell because of the activity of Na
+
/K
+
-ATPases. When potassium channels open 
(activate), K
+
 tends to leak out of the cell, producing a measurable electrical current that 
establishes a charge difference across the membrane (membrane potential). This polarization of 
the membrane is the basis of cellular electrical signaling. 
  
1.3.2. Voltage-activated potassium channels 
Voltage-activated potassium channels (Kv channels) are a subset of the K
+
 channels 
which are sensitive to changes of the cell's membrane potential. They play a crucial role during 
action potentials in returning the depolarized cell to a resting condition. Kv channels are 
activated at relatively negative potentials (~ -60 mV, close to the resting potential for many 
excitable cells). Thus, Kv outward currents determine at least partly the membrane resting 
potential. 
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Structure 
The typical Kv channel represents an assembly of four identical (or similar) 
transmembrane subunits surrounding a central pore (fig. 1.2 A, B).  
Both NH2- and COOH- termini of the subunits are situated on the intracellular side of the 
membrane. Each subunit has six transmembrane crossing segments (S1–S6). Different segments 
form physiologically important structures. The segments S1–S4 constitute a voltage sensor (the 
S4 region has multiple positive charges), S5 and S6 form a pore, the central structure of Kv 
channels. The narrowest part of the pore, the selectivity filter, is formed by the loop between S5 
and S6. The parts of the subunits responsible for ion selectivity were discovered during channel 
mutation studies. The selectivity filter of Kv channels includes the amino acid sequence Thr-Val-
Gly-Tyr-Gly (Doyle et al., 1998).  
Opening and closing of the pore regulates the ion transport through the membrane. 
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Figure 1.2 Scheme of Kv channel architecture.  
A. Longitudinal section of the Kv channel (presented is one subunit from four). Conformations: I 
– “paddle” -open/close conformation; II – selectivity filter-inactivation; III – S6-inactivation; IV 
– “ball-and-chain” inactivation. Green arrows indicate activation of the Kv channel, red – 
inactivation. B. Cross section of the Kv channel.  
A B 
  
 
- 11 - 
Gating 
Gating is a set of conformational changes resulting in opening and closing of the Kv 
channel pore (Yellen, 2002). The voltage sensor is responsible for the gating, it contains a region 
“paddle” composed of the S3 and S4 segments (fig. 1.2 A). When the membrane potential 
becomes more positive inside the cell (depolarisation), the voltage sensor initiates channel 
opening (activation) which leads to K
+
 efflux. The opposite change of the membrane potential 
(hyperpolarisation) leads to the movement of the “paddle” into the closed conformation.  
Besides gating there is also an inactivated conformation; in this case the channel cannot 
open, even if the transmembrane voltage is suitable. Inactivation is governed by several 
mechanisms. The three most known mechanisms are S6-, pore- (“selectivity filter”) and NH2- 
(“ball-and-chain”) inactivation (fig. 1.2A). In the case of the “ball-and-chain” inactivation, the 
NH2-terminus of the channel’s subunit forms a ball which is connected to the rest of the protein 
through a loop (the chain). During inactivation, the ball moves into the inner porehole, and 
doesn’t allow ions to move through the channel (Armstrong et al., 1973; Murrell-Lagnado et al., 
1993). 
Depolarization of the cell membrane activates Kv channels. It works also as the 
inactivating factor for many Kv channels. Thus, the amount of current flowing through the Kv 
channel represents the result of the balance between channel activation and inactivation 
processes (Nelson et al., 1995). 
 
Blockers of Kv channels  
Kv channels are blocked by Ba
2+
 ions: half-block occurs at concentrations > 1 mM 
(Pfrunder et al., 1992). 
The canonical pore-blocking substance tetraethylammonium (TEA) inhibits most Kv 
channels at higher concentrations then KCa channels: half-block is observed at 10 mM (Overturf 
KE et al., 1994). 
4-aminopyridine (4-AP) is widely used as an inhibitor of vascular smooth muscle Kv 
channels because of its selectivity: half-block is seen at 0,2-1,1 mM (Hara et al., 1980). 
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Some other Kv channel inhibitors have been described: phencyclidine (Robertson et al., 
1994), tedisamil, a class 3 antiarrhythmic (Pfrunder et al., 1992), and quinidine (Beech et al., 
1989).  
Glibenclamide, charybdotoxin and iberiotoxin, inhibtors of non-Kv channels expressed in 
vascular smooth muscle cells, have no blocking effect on Kv channels. 
 
1.2.3. The KCNQ subfamily 
Voltage-activated potassium channels include the KCNQ (Kv7) subfamily. 
Architecturally, KCNQ channels are similar to other Kv channels, but they possess a long and 
variable C-terminus (Schmitt et al., 2000). Other distinctions of the KCNQ subfamily such as 
pharmacologic, biophysical and physiologic features will be reviewed later.  
 
Variety of KCNQ channels 
The KCNQ family includes five subtypes encoded by five genes (KCNQ1-5). KCNQ 
channels are present in different excitable tissues.  
KCNQ1 channels are found predominantly in the heart. In contrast to other KCNQ 
members, KCNQ1 (KvLQT1) is not expressed in neurons (Jespersen et al., 2005) and can form 
only homomeric channels of four identical (KCNQ1) transmembrane subunits (Schwake et al., 
2003). KCNQ1 is insensitive to activators of other KCNQ channels (Gamper et al., 2005; Munro 
et al., 2007).  
KCNQ1 channels produce a slow delayed-rectifier K
+
 current (IKs) which is important for 
the repolarization of the cardiac action potential. These channels play a crucial role in the 
forming of the QT interval of the electrocardiogram. Mutations affecting the function of KCNQ1 
channels could lead to the long QT syndrome dangerous because of the induction of arrhythmias, 
ventricular fibrillation, and cardiac arrest (Chiang et al, 2000; Herbert et al., 2002; Jespersen et 
al., 2005).  
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Members of the KCNE family of Kv channels can interact with KCNQ1 with varying 
effects on channel function (McCrossan et al., 2004; Jespersen et al., 2005). 
KCNQ2 and KCNQ3 subtypes are mostly present in the nervous system. They create a 
heteromeric complex. These channels produce ACh-regulated M-currents important for neuronal 
excitability. Mutations in KCNQ2 and KCNQ3 channels lead to Benign Familial Neonatal 
Convulsions (BFNC), a subtype of generalized epilepsy (Charlier et al., 1998). 
KCNQ4 channels locate mostly in neurons, sensory cells of the cochlea and vestibular 
organs. These subtypes can form homomeric and also heteromeric channels (in association with 
the KCNQ3 subtype). Defects in KCNQ4 lead to the nonsyndromic sensorineural deafness type 
2 (DFNA2), an autosomal dominant form of progressive hearing loss (Kubisch et al., 1999).  
KCNQ5 channels are expressed in some neurons and in other excitable tissues, including 
visceral smooth muscle (Jensen et al., 2005) and skeletal muscle (Lerche et al., 2000; Schroeder 
et al., 2000). KCNQ5 also have been found to interact with KCNQ3 channels. 
 
Biophysics and functions 
KCNQ channels represent a slowly inactivating or non-inactivating (delayed rectifier) 
channel. These channels are very important for excitable tissues because of their role in the 
regulation of the membrane potential (Robbins, 2001; Delmas et al., 2005). Based on 
investigations of mutations in the KCNQ channel genes leading to several human diseases it was 
possible to analyze their functions (Brown, 2008). 
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Pharmacology 
KCNQ channels have a unique pharmacology. Due to the existence of highly selective 
blockers it was possible to get more information concerning their properties in many tissues, 
including vascular smooth muscle (fig. 1.3). The classical K
+
 channel blockers 
tetraethylammonion (TEA) and 4-aminopyridine (4-AP) inhibit a large majority of Kv channels, 
but from the KCNQ family only KCNQ2 is blocked by TEA (KCNQ2 alone: 0.16 mM; 
KCNQ2/KCNQ3: 0.5 mM) (Wang et al., 1998; Robbins, 2001). KCNQ channels are largely 
resistant to 4-AP. Chromanol 293B (C293B), linopirdine (DuP 996) and its more potent 
analogue 10,10-bis(4-pyridinyl-methyl)-9(10H)-anthracenone or XE991 (Earl et al., 1998) are 
potent and selective blockers of KCNQ channels (Jentsch, 2000; Robbins, 2001). The activity of 
these channels is enhanced (through an activation voltage-shift) by an anticonvulsant, retigabine.  
Chromanol 293B Linopirdine XE991
 
Figure 1.3 KCNQ channel blockers.  
 
At concentrations of 10 µM or less linopirdine and XE991 are effective and relatively 
selective blockers of all five subtypes of KCNQ channels, other types of K
+
 channels these drugs 
influence at higher concentrations (Schnee et al., 1998; Wladyka et al., 2006).  
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Flupirtine [ethyl-N-[2-amino-6-(4-fluorophenylmethyl-amino)pyridine-3-yl]carbamate] 
and retigabine [ethyl-N-[2-amino-4-(4-fluoro-phenylmethyl-amino)phenyl]carbamate] are 
commonly used activators of KCNQ channels (fig. 1.4). Chemically they differ only by one 
nitrogen atom. They activate all of the subtypes except KCNQ1.  
Flupirtine Retigabine
 
Figure 1.4 KCNQ channel activators.  
 
 
The structurally dissimilar agent, Bristol-Myers Squibb compound (Acrylamide S-1) 
blocks KCNQ1 and activates KCNQ2-5 currents (Bentzen et al., 2006). 
 
Regulation 
M-currents (currents produced by neuronal KCNQ channels) are inhibited by activation 
of M1 muscarinic acetylcholine receptors. 
KCNQ channels are also regulated by membrane phosphatidyl-inositol-4,5-bisphosphate 
(PIP2) and variably by intracellular Ca
2+
 (via channel-associated calmodulin) and by protein 
kinase C (PKC), and are inhibited by transmitters acting on receptors coupled to the G proteins 
Gq and G11 (Selyanko et al., 2000), providing a mechanism whereby such transmitters can 
increase neuronal excitability (Brown, 1983). They are involved in the regulation of nociceptive 
transmission (Passmore et al., 2003). 
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1.4. KCNQ channels in blood vessels  
 
In contrast to the extensive research of KCNQ channels in the CNS and heart, there are 
only a few studies on these channels in smooth muscle cells (SMCs).  To date, KCNQ1 
transcripts have been identified in the rat stomach (Ohya et al., 2002) and the murine portal vein 
(Ohya et al., 2003). More recently KCNQ4 and KCNQ5 were also found to be expressed in the 
murine portal vein (Yeung et al., 2008). Examination of KCNQ channel gene expression in 
arterial smooth muscle cells from different vessels such as the thoracic aorta, carotid artery and 
femoral artery of mice showed transcripts for KCNQ1, KCNQ4 and KCNQ5 (Yeung et al., 
2007). The expression of KCNQ1, KCNQ4 and KCNQ5 was shown in adult rat aorta; A7r5 cells 
derived from this vessel expressed only KCNQ5 (Brueggemann et al., 2007). KCNQ1, 4 and 5 
transcripts were also found in rat mesenteric artery smooth muscle cells (Mackie et al., 2008a) 
that confirms the findings in murine mesenteric artery. KCNQ1, 3, 4 and 5 transcripts were 
found in rat pulmonary artery, myocytes from this vessel did not contain KCNQ3 message (Joshi 
et al., 2009). The newest data show the presence of KCNQ1, 4 and 5 messages in smooth muscle 
cells from rat middle cerebral arteries (Zhong et al., 2010). All KCNQ genes except the KCNQ2 
member were expressed in 2 kinds of human vessels: arteries from visceral adipose tissue and 
proximal mesenteric arteries (Ng et al., 2011). 
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Physiological roles 
The vasoconstrictor hormone Arg
8
-vasopressin (AVP) inhibits KCNQ5 channels in A7r5 
smooth muscle cells (Brueggemann et al., 2007). Vasoconstriction occurs as the result of AVP 
binding to Gq-coupled V1a vasopressin receptors (fig. 1.5). The effects of AVP are protein kinase 
C (PKC)-dependent: they disappear after PKC inhibition by calphostin. PKC-dependent 
inhibition of KCNQ currents by AVP causes membrane depolarization and activation of L-type 
Ca
2+
channels, resulting in Ca
2+ 
entry and cellular contraction.  
 
Figure 1.5 Effects of AVP: red line indicates inhibitory action, green lines - stimulatory action. 
 
This was the first evidence that vascular KCNQ channels may play a role as targets of 
vasoconstrictor hormones. Later, an AVP-induced inhibition of KCNQ5 channels was also found 
in the rat mesenteric artery (Mackie et al., 2008a). In summary, information about the 
contribution of KCNQ channels to vascular contractility are very limited.  
V1a 
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1.5. Hypothesis 
 
The investigation of KCNQ channels in the circulatory system is a relatively new area in 
physiology. However, the participation of KCNQ channels in vessel contractility regulation, 
especially in relaxation mechanisms, is still not well known. Some data were obtained by 
studying the effects of the KCNQ channel activators retigabine and flupertine. But the 
involvement of KCNQ channels in vessel responses to endogenous vasodilator substances has 
not been reported yet. Therefore, we have tested the hypothesis that KCNQ channels are 
powerful targets for relaxation of small systemic and pulmonary arteries. 
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2. MATERIAL AND METHODS 
 
2.1. Material 
 
Experimental subjects: 
The experiments presented in this work were performed on male normotensive Wistar 
and spontaneously hypertensive SHR rats. The animals were kept under standard laboratory 
conditions with free access to food and water. Rats 10-15 weeks old had body weights between 
250-300 g. All experiments conformed to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH publication no. 85-23 revised 1996). 
Materials: 
The following chemicals and kits were used (table 2.1): 
 
Procedure Name Firma Order number 
RNA-isolation 
RNeasy Fibrouse Tissue Mini Kit (50) Qiagen Cat. No.74704 
RNase-Free DNase Set (50) Qiagen Cat. No. 9254 
RT-PCR 
Transcriptor One-Step RT-PCR Kit (50) Roche Cat. No. 04655877001 
PCR-Master Roche Cat.No. 11636103001 
Primers (table 2.2) Qiaqen on demand 
Visualisation 
of 
PCR results 
Agarose   
Tris-base   
Boric acid   
EDTA   
Ethidium bromide   
DNA marker   
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Myography 
Acetylcholine   
Phentolamine   
XE991 Tocris  
EGTA   
Preconstrictors 
Serotonin Sigma-Aldrich  
U46619 Sigma-Aldrich  
Phenylephrine Sigma-Aldrich  
KCNQ 
openers 
Retigabine Valeant 
Research 
North 
America 
 
VRX0530727  
VRX0621238 (ICA-27243)  
VRX0621688  
 Table 2.1 Chemicals and kits. 
 
2.2. Methods 
 
The expression of KCNQ channels in Gracilis arteries, a representative of a small artery 
of the systemic circulation, was studied using the PCR-method. The functional effects of KCNQ 
channel openers were investigated on isometric preparations of intact Gracilis and 
Intrapulmonary arteries using wire myography.  
 
2.2.1. PCR 
Each kind of KCNQ channel basically represents a unique complex of transmembrane 
proteins. The amino acid sequence of these proteins is known and coded by a sequence of 
nucleotide triplets represented by mRNA. The presence of these mRNA molecules in the cell is a 
prerequisite for the presence of KCNQ channels. Thus, the existence of a certain mRNA in the 
vessel suggests the expression of the corresponding channel in this tissue. For the isolation of 
mRNA from Gracilis arteries the RNeasy Fibrouse Tissue Mini Kit (Qiagen) was used. 
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Practically it is not possible to read nucleotide sequences from mRNA. So it is necessary 
to get the complimentary DNA fragment (cDNA) from the mRNA molecule by reverse 
transcription.  
For the different KCNQ channels we used the following specific primers (table 2.2).  
 
Gene Primer Primer Pair Sequences (5'-3') Predicted Size 
KCNQ1 
forward ggc ata ctt ggc tct ggg ttt g 
486 base pairs 
reverse gca gct gtg aca cat ggg tga tg 
KCNQ2 
forward acg cct tct acc gca agc tgc 
363 base pairs 
reverse aag aca ttg ccc tgg gag cc 
KCNQ3 
forward aag acc aaa gca tga tgg gga agt t 
764 base pairs 
reverse tgg aag ggg tcc ata tgg aat ctg 
KCNQ4 
forward cgc ttc cgg gcc tct cta aga c 
560 base pairs 
reverse gtc ctc gtg gtc tac agg gct gtg 
KCNQ5 
forward gat gcc agt gtg acg tgt ccg tgg 
392 base pairs 
reverse cct ttc cga gga cct gct ggt ag 
Table 2.2 Primer pair sequences used for KCNQ channel identification. 
 
After reverse transcription (T=45°C, 30 minutes) cDNA enters into the polymerase chain 
reaction (PCR) which consists of 3 principle stages (repeat: 35 cycles): 
1. Denaturation (T=94°C, 2 minutes) – dissociation of the RNA/cDNA hybrid, melting of 
the cDNA template by disrupting the hydrogen bonds between complementary bases 
yielding single strands of DNA.  
2. Annealing (T=56°C, 30 seconds) – annealing of the primers to the single-stranded DNA 
template. 
3. Elongation (T=68°C, 1 minute 10 seconds) – the DNA polymerase synthesizes a new 
DNA strand complementary to the DNA template strand by adding dNTPs 
(Deoxynucleotide Triphosphates) that are complementary to the template in the 5' to 3' 
direction.  
All steps were performed using the Transcriptor One-Step RT-PCR Kit (Roche). 
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Procedure of working with ready kits 
 
2.2.1.1. RNA isolation from Gracilis arteries 
1) Rats were sacrificed by decapitation, Gracilis arteries from both legs were isolated 
quickly under the microscope and placed into a small (0,5ml) glass tube for 
homogenization. 
2) 200µl RNase-free water, 50µl of ready to use RLT Buffer (with β-ME) and 20µl of 
Proteinase K from the RNeasy Fibrouse Tissue Mini Kit (Qiagen) were applied.  
3) The tissue was thoroughly disrupted and homogenized using a glass pestle.  
4) The mixture was transferred to a 1,5ml plastic tube and 200µl RNase-free water 
was applied.  
5) The resulting solution was incubated at 55°C for 10 minutes and mixed with 
ultrasound.  
6) 250µl of 96–100% ethanol was applied and mixed.  
7) The sample was transferred to the RNeasy column (from the kit), centrifuged for 15 
seconds at ≥8000 x g, and the flow-through was discarded.  
8) 350µl RW1 Buffer was applied to the RNeasy column, centrifuged for 15 seconds 
at ≥8000 x g, and the flow-through was discarded.  
9) A mix of 10μl DNase stock solution and 70μl RDD Buffer (from RNase-Free 
DNase Set, Qiagen) was applied to the RNeasy membrane and incubated for 15 min 
at 20–30°C.  
10) 350µl RW1 Buffer was applied to the RNeasy column, centrifuged for 15 seconds 
at ≥8000 x g, and the flow-through was discarded.  
11) 500µl ready to use RPE Buffer (with ethanol) was applied to the RNeasy column, 
centrifuged for 15 seconds at ≥8000 x g, and the flow-through was discarded.  
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12) 500µl ready to use RPE Buffer (with ethanol) was applied to the RNeasy column, 
centrifuged for 2 minutes at ≥8000 x g, and the flow-through was discarded.  
13) The RNeasy column was placed in a new 1,5ml tube, 50μl RNase-free water was 
applied and centrifuged for 1 minute at ≥8000 x g. The eluate contained the RNA to 
be investigated.  
For positive controls RNA was isolated from brain and heart of the animal. Here, 30 mg 
of tissue was used. The RNA-isolation procedure was the same as described above and in the 
RNeasy Fibrouse Tissue Mini Kit manual. 
 
2.2.1.2. RT-PCR 
RT-PCR was performed according to the instruction of the Transcriptor One-Step RT-
PCR Kit (Roche). Initially, primers, 5xReaction buffer and Transcriptor enzyme mix from the kit 
as well as RNA template were put on ice. The following mix of the constituents was prepared 
(table 2.3): 
 
  for 1 tube, µl for 5 normal tubes, µl 
template RNA 3,00 15,00 
Sterile H2O 10,15 50,75 
5x Reaction buffer  5,00 25,00 
Transcriptor Enzyme mix 0,25 1,25 
Summary volume 18,40 92,00 
Table 2.3 Working PCR mix. 
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Samples were put into the PCR-machine (Mastercycler gradient, Eppendorf) and the PCR 
program (see attachment I) was started. After the first pause, each primer pair mix: 3,3µl forward 
+ 3,3µl reverse primer (concentration 3*10-6M) was applied to the corresponding tubes. The 
PCR program was continued. Then, the control mix (table 2.4) for the control tubes was prepared 
using the PCR-Master kit (Roche): 
 
  for 1 tube, µl for 5 normal tubes, µl 
template RNA 3,00 15,00 
Sterile H2O 2,90 14,50 
Special PCR-Master 12,50 62,50 
Summary volume 18,40 92,00 
Table 2.4 Control Mix with PCR-Master kit. 
 
Control tubes were put into the PCR-machine at the second pause, the primer mix was 
applied as described above and the PCR program was continued. After completion of the 
program all tubes were allowed to cool down. In addition, an 1,6% agarose gel (table 2.5, table 
2.6) containing 12 slots was prepared. 
 
 for 100ml 
Agarose 1,6g 
TBE*10 solution 5ml 
Ethidium bromide 40µl 
Table 2.5 Agarose gel. 
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 for 1 l 
Tris-base 108g 
Boric acid 55g 
EDTA 9,3g 
Table 2.6 TBE*10 solution. 
 
The gel was placed into the standard Gel Electrophoresis system filled with TBE Buffer. 
In each slot a mix of 8µl DNA, 3µl Blue ink and 4µl water was applied. The first and last slots 
were used to load DNA-markers (table 2.7). 
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DNA 
name D
N
A
 
m
a
rk
e
r 
K
C
N
Q
1
 
K
C
N
Q
1
 
c
o
n
tr
o
l 
K
C
N
Q
2
 
K
C
N
Q
2
 
c
o
n
tr
o
l 
K
C
N
Q
3
 
K
C
N
Q
3
 
c
o
n
tr
o
l 
K
C
N
Q
4
 
K
C
N
Q
4
 
c
o
n
tr
o
l 
K
C
N
Q
5
 
K
C
N
Q
5
 
c
o
n
tr
o
l 
D
N
A
 
m
a
rk
e
r 
µl 1 8 8 8 8 8 8 8 8 8 8 1 
ink µl 3 3 3 3 3 3 3 3 3 3 3 3 
water µl 11 4 4 4 4 4 4 4 4 4 4 11 
Table 2.7 Template disposition on the gel. 
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2.2.2. Wire myography 
Rats were sacrificed by decapitation. Thereafter, arteries were isolated from the animal 
and mounted on the small vessel myograph. Vessel reactivity was evaluated by measuring 
isometric tension.  
 
2.2.2.1. Vessel isolation 
The experiments reported in this study were performed on systemic small arteries and on 
pulmonary arteries. In particular, fragments of Gracilis arteries (Fig. 2.1, A) and Intrapulmonary 
arteries (Fig. 2.1, B) with an internal diameter of about 300 µm were chosen. At the beginning, a 
leg or the lung was cut off and placed into cooled (4°C) preparation solution (solution II, see 
attachment II). The arteries were carefully cleaned from connective tissue under the microscope 
using small forceps and scissors. Thereafter, they were dissected into 2 mm rings, transferred to 
the myograph chamber and mounted on the wires. In some cases the endothelium was removed 
using a rat’s whisker (Schubert, 2004). 
                                        
         A          B 
Figure 2.1 Scheme of vessels localisation: A – medial surface of the left hindlimb: a) a. saphena, 
b) a. gracilis, c) m. gracilis; B – lower lobe of the left lung (dorsal surface): a) a. pulmonalis 
sinistra, b) 3
rd
 order branch of a. pulmonalis (Intrapulmonary artery)
a 
b 
a 
b 
c 
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2.2.2.2. Principle of myography 
In this work, a 2-channel DMT myograph (model 410A) was used. Each channel contains 
two stainless steel jaws. Two mounting wires (diameter 40 µm) were threaded through the vessel 
lumen and each wire was secured to the jaws (see Fig. 2.2). One of the mounting jaws was 
attached to a micropositioner for the adjustment of vessel circumference and the application of 
tension. The other jaw was attached to a built-in sensitive force transducer.  
 
 Figure 2.2 Scheme of vessel fixation on the mounting jaws. Vessel segments are threaded on 2 
stainless steel wires that are fastened to a force transducer and a micrometer. (Mulvany et al., 
1977). 
 
After vessels mounting, the myograph was connected to the computer and the recording 
program Myodaq 2.01 (Myonic Software) was started. Thereafter, the myograph was heated up 
to 37°C during 30 minutes. To achieve optimal conditions for determining vessel contractility, 
the so called normalization procedure was performed (Mulvany et al., 1977).  
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2.2.2.3. Normalization procedure 
In practice, the normalization is performed by distending the segment stepwise with use 
of the micropositioner and taking sets of micrometer and force readings (Fig. 2.3). These data are 
converted into values of internal circumference (in μm) and wall tension T (in mN/mm) 
respectively (DMT 410A, User Manual). 
 
.  
Figure 2.3 Illustration of the stepwise normalization procedure (picture taken from the user 
manual 410A). 
 
Plotting wall tension against internal circumference reveals an exponential curve and by 
applying the isobar curve corresponding to 100 mmHg for Gracilis arteries or 15 mmHg for 
Intrapulmonary arteries, respectively the IC100 (IC15 for Intrapulmonary artery) is calculated 
from the point of intersection using the Laplace relation (Fig. 2.4). IC100 (IC15) is the internal 
circumference of the vessel at 100 mmHg (15 mmHg). 
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Figure 2.4 Illustration of the exponential curve fitting and determination of IC100 (picture taken 
from the user manual 410A). 
 
 
Thereafter, the internal circumference at which the active force production as well as the 
sensitivity to agonists of the segment is maximal (IC1) was calculated from IC100 (IC15) by 
multiplying the latter by a certain factor. The factor used in this work was 0.9, thus 
IC1=0,9xIC100 (IC1=0,9xIC15), as established by Mulvany et al. (Mulvany et al., 1977). 
After the normalisation procedure, the preparation solution in the myograph chambers 
was changed to the experimental solution (solution I, see attachment II) that was oxygenated 
constantly with a gas mixture of 95% O2 and 5% CO2 in the experiments with Gracilis arteries. 
The experimental solution for Intrapulmonary arteries contained no NaHCO3 (Joshi et al., 2009) 
and was called solution I without NaHCO3 (see attachment II), which was aerated with air. Ten - 
fifteen minutes after normalization the main experiment was started.  
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2.2.2.4. Experimental protocols 
For the investigation of the effect of KCNQ channel openers, the arteries were 
preconstricted to a level of about 30-50% of maximal possible constriction. After stabilization of 
preconstriction, a substance to be studied was applied by adding increasing doses in a stepwise 
manner yielding a dose-response relationship (Fig. 2.5). The maximum contraction of each 
vessel was determined using solution I, where 120 mM KCl was added and a corresponding 
amount of NaCl was removed and 10
-5
 M serotonin was applied. The removal of all tested 
substances was done by a wash out procedure: the solution in the experimental chamber was 
changed to the normal experimental solution 3 times, one more time after 5 minutes and once 
more after 10 minutes. After solution changes, vessels were allowed to equilibrate for 5 minutes. 
For vessel preconstriction one of the following substances was used: serotonin, U46619, or 
phenylephrine. In some cases also solution I, where 60 mM KCl was added and a corresponding 
amount of NaCl was removed was used for preconstriction.  To determine the fully relaxed 
state of the vessel, 2x10
-3
M EGTA was added into the experimental solution at the end of an 
experiment. In some cases, when the endothelium was removed, acetylcholine (10
-5
M final 
concentration) was used to test for successful functional removal of the endothelium.     
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Figure 2.5 Original trace, illustrating the general protocol of the experiments testing KCNQ 
channel openers: 1-normalization, 2-stabilization after normalization, 3-initial contraction in 
120mM KCl + 10
-5
M serotonin, 4-wash out, 5-dose-response curve for preconstrictor, 6-wash 
out, 7-preconstriction, 8-step-wise addition of KCNQ channel opener (addition shown by small 
arrows), 9-full relaxation, 10-wash out. Big arrow shows the usual artifact caused by changing 
the solution in the chamber. 
All values are given as mean ± SEM.  Paired and unpaired Student‘s t tests or ANOVA 
were used as appropriate. A value of p <0.05 was considered statistically significant; n represents 
the number of animals tested.  
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 
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3. RESULTS 
 
In order to test the hypothesis of the present study, KCNQ channel expression in Gracilis 
arteries was investigated using the PCR technique and KCNQ channel function in these vessels 
was evaluated using wire myography. 
 
3.1. Expression of KCNQ channels in rat Gracilis arteries 
 
The PCR-based experiments were performed to clarify the presence of KCNQ channels 
in Gracilis arteries and to determine their subtypes.  
In Gracilis arteries we found mRNA expression for KCNQ1, KCNQ3, KCNQ4 and 
KCNQ5 channels (Fig. 3.1). Similar findings were obtained in 4 other experiments. 
For positive controls, brain and heart was used. Expression of all KCNQ channels tested 
was found in control tissues. To show that isolated mRNA and other reagents had no DNA-
contamination, a negative control was done. To prepare negative controls, the RT-step (reverse 
transcription) was omitted.  
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Figure 3.1 Detection of KCNQ1, KCNQ3, KCNQ4 and KCNQ5 by PCR in isolated rat Gracilis 
arteries. Positive control: heart or brain tissues; negative control: Gracilis arteries without RT-
step.  
The presence of KCNQ channel mRNAs in Gracilis arteries initiated the following series 
of experiments aimed at determining the functional role of these channels.  
 
3.2. Functional effect of KCNQ channel opener on rat Gracilis arteries 
 
These experiments were done to determine the influence of KCNQ channel opening on 
the contractile properties of Gracilis arteries.    
Functional effects of KCNQ channel opener were studied on arteries preconstricted with 
different contractile agents (serotonin, phenylephrine or U-46619). Experimental KCNQ channel 
opener were applied stepwise with the following final concentrations: 10
-8
, 3*10
-8
, 10
-7
, 3*10
-7
, 
10
-6
, 3*10
-6
, 10
-5
 and 3*10
-5
M. The interval between subsequent concentrations was 3-5 minutes. 
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3.2.1. Effects on serotonin-preconstricted Gracilis arteries 
All three substances, VRX0530727, VRX0621238 and VRX0621688, relaxed Gracilis 
arteries preconstricted with serotonin (n=8; p<0.01; n=9; p<0.01 and n=7; p<0.01, respectively).  
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Figure 3.2 KCNQ channel opener relax serotonin-preconstricted Gracilis arteries.  
 
The relaxation was similar for all substances (n=8 for VRX0530727, n=9 for 
VRX0621238, n=7 for VRX0621688; p=0.39; Fig. 3.2). 
 
  
 
- 35 - 
3.2.2. Effects on phenylephrine-preconstricted Gracilis arteries 
In order to determine whether the effect of the KCNQ channel opener depends on the mode 
of preconstriction, vessels were also preconstricted with phenylephrine.   
Under these conditions, only VRX0621238 and VRX0621688 produced considerable 
relaxation (n=7; p<0.01 and n=9; p<0.01, respectively; Fig. 3.3), whereas VRX0530727 did not 
alter vessel tension (n=6; p=0.07).  
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Figure 3.3 KCNQ channel opener relax phenylephrine-preconstricted Gracilis arteries.  
 
In addition, the relaxing effect of VRX0621238 and VRX0621688 was different (n=7 for 
VRX0621238, n=9 for VRX0621688; p<0.01; Fig. 3.3). 
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3.2.3. Effects on U-46619-preconstricted Gracilis arteries 
 To confirm that the effect of the KCNQ channel opener depends on the mode of 
preconstriction, another substance, the thromboxane-analogue U-46619, was used to preconstrict 
the vessels.    
 Under these conditions, VRX0621238 and VRX0621688 produced considerable 
relaxation (n=11; p<0.01 and n=9; p<0.01, respectively; Fig. 3.4). VRX0530727 produced 
vessels constriction (n=6; p<0.05).  
The relaxing effect of VRX0621238 and VRX0621688 was different (n=11 for 
VRX0621238, n=9 for VRX0621688; p<0.01; Fig. 3.4). 
 These data show that the KCNQ channel opener VRX0621238 and VRX0621688 are 
potent vasodilators acting largely independent of the mode of preconstriction. In order to be able 
to study the effect of these substances in more detail without consideration of the mode of 
preconstriction, serotonin was used to preconstrict the vessels in the following experiments.  
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Figure 3.4 KCNQ channel opener relax U46619-preconstricted Gracilis arteries. 
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3.3. Mechanism of action of KCNQ channel opener 
The mechanism of action of the KCNQ channel opener was studied to better understand the 
relationship between KCNQ channel opening and vessel relaxation. As a representative of the 
opener tested, VRX0530727 was used. 
 
3.3.1. Role of the endothelium 
To identify the contribution of the endothelium to the relaxing effect of the KCNQ 
channel opener, the endothelium was functionally removed using a rat’s whisker. Removal of the 
endothelium did not affect the relaxation of Gracilis arteries preconstricted with serotonin by 
VRX0530727 (n=7; p=0.67; Fig. 3.5). Hence, the endothelium plays no role in the relaxation of 
the vessels induced by VRX0530727. 
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Figure 3.5 VRX0530727 relaxes serotonin-preconstricted Gracilis arteries with (+E) and 
without (-E) endothelium.  
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3.3.2. Role of sympathetic nerve endings 
To determine whether sympathetic nerve endings contribute to the vessel relaxation 
induced by VRX0530727, another set of experiments was performed. The influence of 
sympathetic nerve endings was functionally eliminated by blocking postsynaptic receptors with 
phentolamine at a concentration of 10
-6
 M.   
 The relaxation of Gracilis arteries preconstricted with serotonin by VRX0530727 
in the presence of intact and blocked sympathetic nerve endings was not different (n=4; p=0.94; 
Fig. 3.6). We determined that sympathetic nerve endings were not involved in the relaxation of 
the vessels induced by VRX0530727. 
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Figure 3.6 VRX0530727 relaxes serotonin preconstricted Gracilis arteries in the presence of 
intact and phentolamine-blocked (+phe) sympathetic nerve endings.  
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3.3.3. Contribution of K+ channels 
The substances tested in this study have been reported to show a potent opening effect on 
KCNQ channels in expression systems. Therefore, we tested the contribution of K
+
 channels to 
the relaxation of an intact vessel induced by VRX0530727.  
In a first series of experiments, K
+
 channels were functionally eliminated by rising the 
extracellular potassium concentration to 60mM. This brings the actual membrane potential close 
to the potassium equilibrium potential and, therefore, suppresses potassium fluxes through open 
potassium channels. In order to prevent transmitter release from nerve endings evoked by KCl-
induced depolarization, vessels were additionally treated with phentolamine.  
The relaxation of Gracilis arteries preconstricted with serotonin and with 60mM KCl by 
VRX0530727 was different, KCl-induced preconstriction reduced the relaxation induced by 
VRX0530727 (n=5; p<0.01; Fig. 3.7).  
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Figure 3.7 VRX0530727 relaxes Gracilis arteries preconstricted with KCl in the presence of 
phentolamine (KCl + phe) less than vessels preconstricted with serotonin (Ser). 
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These data suggest that K
+
 channels contribute to the relaxation of the vessels by 
VRX0530727. 
3.3.4. Involvement of KCNQ channels 
In a second series of experiments, the contribution of KCNQ channels to the relaxation 
induced by VRX0530727 was tested. For this purpose, the specific KCNQ channel inhibitor 
XE991 at 10
-5
M was used. 
In the presence of XE991, the relaxation of Gracilis arteries by VRX0530727 was 
considerably reduced (n=5; p<0.01; Fig. 3.8). Thus, channels from the KCNQ family mediate the 
VRX0530727-caused relaxation of Gracilis arteries. 
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Figure 3.8 VRX0530727 relaxes serotonin-preconstricted Gracilis arteries in the presence of the 
KCNQ channel inhibitor XE991 (Ser + XE991) less than serotonin-preconstricted vessels in its 
absence (Ser). 
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3.4. Effect of KCNQ channel opener on Gracilis arteries of SHR rats 
Since opening of potassium channels, especially KCNQ channels, might be an interesting 
therapeutic strategy in disease accompanied by increased peripheral vascular resistance, the 
effect of the KCNQ channel opener was tested also on Gracilis arteries from spontaneously 
hypertensive rats (SHR).  
 All three substances, VRX0530727, VRX0621238 and VRX0621688, relaxed Gracilis 
arteries from SHR preconstricted with serotonin (n=4; p<0.01; n=4; p<0.01 and n=4; p<0.05, 
respectively; Fig. 3.9).  
The relaxation was similar for all substances (n=4 for VRX0530727, n=4 for 
VRX0621238, n=4 for VRX0621688; p=0.49) and was not different from their effects in 
normotensive animals (VRX0530727: n=8 for normotensive rats, n=4 for SHR; p=0.28; 
VRX0621238: n=9 for normotensive rats, n=4 for SHR; p=0.51; VRX0621238: n=7 for 
normotensive rats, n=4 for SHR; p=0.63).  
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Figure 3.9 KCNQ channel opener relax serotonin-preconstricted Gracilis arteries from SHR.  
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In addition, we studied the effect of retigabine, a known KCNQ channel opener, on 
Gracilis arteries from spontaneously hypertensive rats.  
 Retigabine relaxed Gracilis arteries from SHR preconstricted with serotonin (n=4; 
p<0.01; Fig. 3.10). 
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Figure 3.10 Retigabine relaxes serotonin-preconstricted Gracilis arteries from hypertensive rats. 
 
Thus, all KCNQ channel opener dilate also arteries from hypertensive rats in the same way 
like in normotensive rats. The KCNQ channel opener tested in this study have the same action on 
Gracilis arteries from hypertensive rats as the potent KCNQ opener Retigabine.  
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3.5. Functional effect of KCNQ channel opener on rat Intrapulmonary 
arteries 
 
All previously described experiments were conducted on a vessel representing the 
systemic circulation. In order to understand whether the KCNQ channel opener act also on the 
pulmonary circulation, additional experiments were performed on isolated Intrapulmonary 
arteries.  
In the experiments with Intrapulmonary vessels, some parameters were changed to 
account for the specific features of the pulmonary circulation, for example the different 
transmural pressure (for more details see methods section). Further, the thromboxane-analogue 
U-46619 was used to preconstrict Intrapulmonary arteries, because preliminary experiments 
showed that this is the only stable preconstrictor for these vessels.  
The vasorelaxing action of the KCNQ channel opener was of primary interest. Thus, the 
effect of VRX0621238 and VRX0621688, producing relaxation of U-46619-preconstricted 
Gracilis arteries, was studied on Intrapulmonary arteries. 
 
3.5.1. Effects on U-46619-preconstricted Intrapulmonary arteries 
VRX0621238 and VRX0621688 relaxed Intrapulmonary arteries (n=9; p<0.01 and n=8; 
p<0.01, respectively). The relaxation was similar for both substances (n=9 for VRX0621238 and 
n=8 for VRX0621688; p=0.27; Fig. 3.11). 
 These experiments show that the KCNQ channel opener VRX0621238 and VRX0621688 
produce a relaxation in the pulmonary circulation resembling their effect on systemic arteries. 
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Figure 3.11 VRX0621238 and VRX0621688 relax U-46619-preconstricted Intrapulmonary 
arteries.  
 
3.5.2. Comparison of the effects on arteries                                                   
of the systemic and pulmonary circulation 
The relaxation of Gracilis and Intrapulmonary arteries preconstricted with U46619 by 
VRX0621238 was different (n=9 for Gracilis arteries and n=7 for Intrapulmonary arteries; 
p<0.01; Fig. 3.12). The effect on Gracilis arteries was stronger. 
In contrast, the relaxation by VRX0621688 was similar (n=9 for Gracilis arteries and n=5 
for Intrapulmonary arteries; p=0.39; Fig. 3.13).  
Thus, the effect of KCNQ channel opener in the systemic and the pulmonary circulation 
is different for VRX0621238 and similar for VRX0621688. 
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Figure 3.12 VRX0621238 relaxes U-46619-preconstricted vessels from the systemic and 
pulmonary circulation.  
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Figure 3.13 VRX0621688 relaxes U-46619-preconstricted vessels from the systemic and 
pulmonary circulation.  
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4. DISCUSSION 
 
This study shows that KCNQ channel mRNA expression in a non-visceral artery, the rat 
Gracilis artery, is not different from other vessels studied previously. We showed for the first 
time that the putative KCNQ channel opener VRX0530727, VRX0621238 and VRX0621688 
have a potent vasorelaxing effect in rat Gracilis arteries. We demonstrated that KCNQ channels 
are involved in the relaxation induced by the KCNQ channel opener. KCNQ channel opener also 
relax arteries from hypertensive rats. In addition, KCNQ channel opener produce a relaxation in 
the pulmonary circulation as well. 
 
4.1. Expression of KCNQ channels in rat Gracilis arteries  
 
In our study on rat Gracilis arteries we found mRNA expression for KCNQ1, KCNQ3, 
KCNQ4 and KCNQ5 channels.  
From previous studies we know that KCNQ1, KCNQ4 and KCNQ5 transcripts are 
present in several, mainly visceral vessels isolated from mouse, rat and humans. In the mouse, 
KCNQ1, 4 and 5 channel messages were found in the portal vein, thoracic aorta, carotid and 
femoral artery (Ohya et al., 2003; Yeung et al., 2007-2008). The same transcripts were detected 
in the rat aorta, mesenteric, pulmonary and small cerebral arteries (Brueggemann et al., 2007; 
Mackie et al., 2008a; Joshi et al., 2009; Zhong et al., 2010). In a study on human arteries from 
visceral adipose tissue and the mesenteric bed the same findings were reported (Ng et al., 2011).  
Transcripts for KCNQ2 channels were always absent in vascular tissue in all previous 
investigations. 
Our findings concerning the presence of KCNQ1, 4 and 5 channels and the absence of 
KCNQ2 transcripts in rat Gracilis arteries confirm data obtained in other vessels studied so far.  
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Expression of mRNA for KCNQ3 channels is not typical for blood vessels. To this 
moment, KCNQ3 transcripts were found only in rat pulmonary arteries (Joshi et al., 2009) and 
some human arteries (Ng et al., 2011). A more detailed analysis of isolated smooth muscle cells 
derived from rat pulmonary arteries demonstrated the absence of KCNQ3 message (Joshi et al., 
2009). Unfortunately, such analysis was not performed on arteries from visceral adipose tissue and 
proximal mesenteric arteries (Ng et al., 2011). Nevertheless, based on these data we suppose that 
KCNQ3 channels may not be present in the smooth muscle cells of Gracilis arteries, but in cells 
of the other layers of the vessel wall. To confirm or refute this supposition, additional studies are 
required using isolated cells, a method not employed in this study.  
Taking all data together, we suppose that KCNQ2 and KCNQ3 channels play no role in 
vascular smooth muscle cells because of their rare existence in this tissue. In addition, we 
suppose that pharmacological interventions targeting these subunits in the nervous system do not 
show side effects in the cardiovascular system. In contrast, KCNQ4 and KCNQ5 channels are 
present in both types of tissues (KCNQ1 is not expressed in the brain) and this may be the reason 
for some unexpected manifestations of drug applications.  For example, the anticonvulsant 
retigabine was used at a concentration of 10µM in the neurvous system and at the same 
concentration it produces significant relaxation of preconstricted vessel (Yeung et al., 2007).  
 
4.2. Functional effect of KCNQ channel opener on rat Gracilis arteries 
 
To this moment, several KCNQ channel opener such as retigabine, flupirtine, acrylamide 
S-1 and the novel KCNQ openers VRX0530727, VRX0621238, and VRX0621688 were 
reported to relax preconstricted isolated systemic arteries. The effects of these substances are 
reversed by KCNQ channel inhibition with XE991 (Yeung et al., 2007; Joshi, et al., 2009; 
Schleifenbaum et al., 2010; Ng et al., 2011). 
In particular, it was shown that retigabine (2 - 20 µmol/l) relaxes segments of mouse 
aorta (preconstricted with phenylephrine) with maximal relaxation of about 40%. Application of 
flupirtine (20 µmol/l) in the same vessels produces also considerable relaxations (Yeung et al., 
2007).  
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Retigabine also produces concentration-dependent relaxation of mouse mesenteric 
arteries preconstricted with serotonin or U-46619 with a half-maximal effect at ~ 3-5 µmol/l. 
Interestingly, the relaxation of serotonin preconstricted vessels was stronger then in case of U-
46619 preconstricted vessels. The same arteries preconstricted with serotonin show significant 
relaxation also after VRX0530727, VRX0621238 and VRX0621688 application (Schleifenbaum 
et al., 2010). 
Recently it was shown that retigabine and acrylamide S-1 (3 – 10 μmol/l) relax 
preconstricted human visceral adipose and mesenteric arteries dose-dependently (Ng et al., 
2011).  
Our experiments show that VRX0530727, VRX0621238 and VRX0621688 relax rat 
Gracilis arteries preconstricted with serotonin in a similar way with a half-maximal effect at ~ 5-
10 µmol/l. These data confirm available information about effect of KCNQ openers on mouse 
mesenteric arteries. 
 
In addition, we tested retigabine on rat Gracilis arteries preconstricted with serotonin 
from hypertensive rats. Retigabine application produced vessel relaxation with a half-maximal 
effect at ~ 3-5 µmol/l. Our findings confirm previous data on vessels from normotensive mice. 
The available data show that the relaxing effect of retigabine does not depend on the vessel type 
studied, but may depend on the way of preconstriction. 
The latter conclusion is supported by our data on the effect of the novel KCNQ channel 
openers in vessels preconstricted with different agents. Thus, Gracilis arteries preconstricted 
with phenylephrine were not affected by VRX0530727. However, VRX0621238 and 
VRX0621688 relax those arteries, but with different half maximal effects (~ 3 and 10 µmol/l 
respectively). In addition, the use of the thromboxane-analogue U-46619 as a preconstrictor 
demonstrates a different result: VRX0621238 and VRX0621688 produce considerable relaxation 
(half maximal effect at ~ 5 and 7 µmol/l respectively) but VRX0530727 produce vessel 
constriction. 
The mechanisms of vessel constriction of the used preconstrictor agents show some 
differences (Fig. 4.1). All substances used bind to their appropriate receptors at the smooth 
muscle cell membrane; serotonin binds to the 5-hydroxytryptamine receptors (5-HT2A), 
phenylephrine – to the α1-adrenoreceptors (α1-ARs) and the thromboxane-analogue U-46619 to 
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the thromboxane A2 receptors (TBXA2R). All these receptors represent G protein-coupled 
receptors (GPCR). There are few different G-protein-mediated signaling pathways depending on 
the sub-classes of G-proteins (Wettschureck et al., 2005). We will discuss two of them which are 
important for smooth muscle cell contraction (calcium-sensitive and -insensitive pathways). 
a) Ca++ dependent contraction (Fig. 4.1, a) 
In this case GPCR represent the Gq/G11 coupled receptors (for example AT1-angiotensin, 
α1, 5-HT2A receptors etc.). When a signal substrate-molecule binds to a GPCR, a G-protein 
becomes activated on the intracellular side. In turn, the G-protein binds and activates 
phospholipase C (PLC), which hydrolyses phosphatidylinositol-4,5-bisphosphate (PtdInsP2) and 
releases inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). In the sarcoplasmic 
reticulum IP3 binds to the appropriate receptors (IP3R) that releases calcium. In the cytosol, Ca
++
 
first binds to calmodulin. The Ca
++
/calmodulin-complex activates myosin light chain kinase 
(MLCK) and this induces increased myosin light chain (MLC) phosphorylation and cell 
contraction. Furthermore, Ca
++
 and released DAG (see above) activate protein kinase C (PKC), 
which leads to L-type calcium channel phosphorylation. This calcium also participates in myosin 
phosphorylation. 
b) Ca++ independent contraction so called Ca++ sensitization (Fig. 4.1, b) 
Most Gq/G11-coupled vasoconstrictor receptors also activate the G12/G13 family of G 
proteins (receptors for endothelin-1, vasopressin, angiotensin II, thrombin, thromboxane A2 
etc.). G12/G13 proteins activate the second signaling pathway for smooth muscle cell contraction 
through RhoA/Rho-kinase activation that leads to MLCP inhibition and an increased MLC 
phosphorylation.  
In addition, PKC activates also CPI-17, the inhibitor of the myosin light chain 
phosphatase (MLCP) catalytic subunit that also increases MLC phosphorylation (Somlyo et al., 
2000). This mechanism plays a minor, transient role in Ca
++
 independent cell contraction. 
It is suggested that from these two mechanisms of vessel contraction Gq/G11 conveys a 
fast, transient response and G12/G13 proteins mediate a sustained, tonic contraction (Hersch et al., 
2004). 
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Figure 4.1 Vessel constriction caused by GPCR activation: GPCR -  G protein-coupled receptor, 
PLC -  phospholipase C, PtdInsP2 - phosphatidylinositol-4,5-bisphosphate, IP3 -  inositol-1,4,5-
trisphosphate, DAG – diacylglycerol, IP3R - inositol-1,4,5-triphosphate receptor, SPR - 
sarcoplasmic reticulum, PKC - protein kinase C, MLCK - myosin light chain kinase, MLCP - 
myosin light chain phosphatase, MLC - myosin light chains; a) calcium-sensitive pathway, b) 
calcium-insensitive pathway. 
 
The membrane potential depolarization associated with the action of the contractile 
agents used leads, along with the two mechanisms producing contraction, also to a compensatory 
activation of Kv and Ca
++
 dependent potassium channels (KCa). Thus, these channels limit the 
agonist-induced contraction. 
However, the contractile agents used in our study employ these mechanisms, the calcium-
sensitive and the calcium-insensitive pathway, to different degrees. Thus, phenylephrine and 
serotonin are using mostly the calcium-sensitive pathway (the contribution of Ca
++
 sensitization 
is very small and realized by the CPI-17 component). In contrast, the U-46619-induced 
contraction is mediated in a large part by the calcium-insensitive contraction mechanism 
(Wettschureck et al., 2005).  
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We suggest that these differences in the intracellular mechanisms employed by the 
contractile agents used in this study explain the variability of the effects of the KCNQ channel 
openers tested.  
All together, we can conclude that the novel KCNQ openers act differently depending on 
the way of vessel preconstriction, but VRX0621238 and VRX0621688 always show a relaxing 
effect, thus they are the most potent vasodilators. 
 
4.3. Mechanism of action of KCNQ channel opener 
 
It seems logic that KCNQ channel openers act on the KCNQ channels located in smooth 
muscle cells of the arterial tunica media. However, such channels may also exist in the 
endothelium or in nerve endings in the vessel wall. Thus, in our study we first investigate if 
tunica intima (endothelium) or tunica adventitia (sympathetic nerve endings) could mediate the 
action of KCNQ channel openers in arteries of the systemic circulation.  
We found that the endothelium plays no role in the relaxation of the vessels induced by 
VRX0530727.  
For these experiments, the endothelium of some vessels was mechanically removed by a 
rat whisker. The endothelial layer was scraped off by several motions of the whisker inserted in 
the vessel lumen. Complete functional destruction of the endothelial cells was confirmed by the 
absence of the response to the application of 10
-5
M acetylcholine on preconstricted arteries. In 
contrast, control arteries demonstrated strong vasorelaxation to acetylcholine application. 
The data about an endothelium independent relaxation induced by VRX0530727 confirm 
previous information. Analogous experiments addressing the role of the endothelium were 
performed on vessels from the pulmonary circulation. They demonstrated that the vasodilator 
action of retigabine occurred independently of a functional endothelium in rat pulmonary arteries 
(Joshi, et al., 2009). 
In addition, we showed that sympathetic nerve endings are not involved in the relaxation 
of vessels induced by VRX0530727. For these experiments, a possible influence from 
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sympathetic nerve endings was blocked by the application of 10
-5
M phentolamine in order to 
prevent the action of transmitter substances released from the nerve endings.  
Taken together it is clear that the target for the new KCNQ openers is the tunica media, 
most likely the KCNQ channels in the smooth muscle cells. 
Indeed, after elimination of the functional impact of K
+
 channels on vessel contractility 
by rising the extracellular potassium concentration to 60 mM, relaxation of the vessels by 
VRX0530727 was significantly decreased.  
The increase of the extracellular potassium concentration changes the equilibrium 
potential for potassium. It is known that the concentration of potassium ions inside the cell is 
normally ~ 25-times higher then in the extracellular surroundings as the result of the activity of 
Na
+
/K
+
-ATPases. Increasing the concentration of potassium ions in the physiological solution 
brings the K
+
 amount inside the cell closer to its amount outside the cell. In this case K
+
 outflow 
through potassium channels is reduced and the K
+
 ions not leaving the cell any more produce a 
depolarization of the membrane potential that brings the membrane potential close to the 
equilibrium potential for potassium. Consequently, the difference between the membrane 
potential and the equilibrium potential for potassium, i.e. the driving force for potassium ions, is 
so small that even in the case of active potassium channels they are unable to affect the 
contractile state of the vessels. . 
The same effect was observed after the selective blockade of KCNQ channels by 10 µM 
of XE991. XE991 produced significant changes: the relaxation of the vessels was blocked 
considerably, but not completely. These data suggest that K
+
 channels and in particular KCNQ 
channels contribute to the relaxation of the vessels induced by VRX0530727. 
In our experiments we used the following concentrations of K
+
/ KCNQ channel blockers: 
60 mM KCl solution and 10
 µM of XE991. At this concentration XE991 is an effective and 
selective blocker for all KCNQ channels (Gutman et al., 2005). The relaxing effect of 
VRX0530727 in our study was blocked incompletely. We will discuss this observation below. 
Our findings on the effect of the new KCNQ channel opener are consistent with 
previously published data. Thus, in mouse thoracic aorta it was shown that retigabine has no 
effect on contractions produced by 60 mM KCl or by 10 µM XE991 (Yeung et al., 2007). In 
addition, in human arteries the relaxation produced by retigabine or acrylamide S-1 was reversed 
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completely by the subsequent application of 10 μM XE991 or was prevented by application of 
XE991 before the preconstriction (Ng et al., 2011). 
The same picture was observed in the pulmonary circulation. The effect of retigabine was 
greatly reduced when pulmonary arteries were preconstricted with 50 mM KCl. Retigabine also 
reduced the vasoconstrictor effects of linopirdine (10 µM) and XE991 (1 µM) almost abolishing 
vasoconstriction at a concentration of 100 µM (Joshi, et al., 2009).  
Finally, relaxation of mouse mesenteric arteries induced by retigabine, VRX0530727, 
VRX0621238, and VRX0621688 was considerably reduced, albeit not completely, after 
inhibition of KCNQ channels with 30 µM XE991 (Schleifenbaum et al., 2010) that confirm our 
data. 
 In our study we observed that blockade of potassium channels and in particular KCNQ 
channels leads to a significant decrease of vessel relaxation induced by VRX0530727. However, 
this blockade did not abolish the relaxation completely.  
Studies on mouse portal vein showed that the half-blocking concentration of XE991 is 
5.8 µM (Ohya et al., 2003). We used 10 μM XE991. At this concentration, KCNQ channels will 
not be blocked completely. However, higher concentrations, that are able to produce a full block 
of these channels, may have side effects not related to KCNQ channels (Zhong et al., 2010). In 
order to be able to draw a clear conclusion from the data obtained, it was decided to use a 
concentration of XE991 that allows a selective action on KCNQ channels even it the block is 
incomplete.   
 
4.4. Effect of KCNQ channel opener on Gracilis arteries of SHR rats 
 
It is known that the expression of Kv channels in vascular smooth muscle cells from 
normo- and hypertensive rats may differ. For example the expression of Kv1.2, Kv1.5 and Kv2.1 
channels is higher in mesenteric arteries of SHR rats compared with normotensive animals. In 
addition, Kv currents associated with these channels are larger in myocytes from SHR 
mesenteric arteries (Cox et al., 2008). 
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We showed here that all KCNQ channel opener and retigabine dilate Gracilis arteries 
from hypertensive rats. Moreover, VRX0530727, VRX0621238, and VRX0621688 act with the 
same potency as in normotensive rats. This demonstrated that the functional availability of 
KCNQ channels is not different between normotensive and hypertensive rats. Although we did 
not investigate the expression of KCNQ channels in the arteries from SHR, these data also 
indicate that KCNQ channel expression is not different in SHR and normotensive rats.  
These findings suggest that the novel KCNQ channel openers may be used as a treatment 
for hypertensive conditions. If one supposes that the high blood pressure does not depend on 
KCNQ channel expression in the vessels, these channels could be used as targets for the 
treatment against hypertension. We suggest that in the future investigations should be performed 
to prove or refute the therapeutic potential of the KCNQ channel openers. In the case that KCNQ 
channel opener may be successfully applied for the treatment of hypertensive conditions, these 
opener may comprise a new class of antihypertensive drugs. 
 
4.5. Functional effect of KCNQ channel opener                                         
on rat Intrapulmonary arteries 
 
From previous studies we know that activation of KCNQ channels is possible also in the 
pulmonary circulation. Thus, in rat intrapulmonary arteries preconstricted with phenylephrine the 
KCNQ channel activator retigabine produced a reduction of the contractile response in a 
concentration-dependent manner with a half-maximal effect at ~ 10 µmol/l (Joshi et al., 2009). 
We determined that the new KCNQ channel opener VRX0621238 and VRX0621688 also 
produce a relaxation in the pulmonary circulation resembling their effect on systemic arteries. 
For our study we used U-46619 for preconstriction because it was the only stable preconstrictor 
for intrapulmonary arteries.  The concentration for the half-maximal effect was approximately 
the same as in a previously published study (Joshi et al., 2009). 
We also found that the effect of KCNQ channel opener in the systemic and pulmonary 
circulation is different for VRX0621238 but similar for VRX0621688, namely VRX0621238 
acts much weaker in the pulmonary circulation. These findings might be useful for the in vivo 
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situation. It is important to take into account that the effect of KCNQ channel opener appears in 
both, systemic and pulmonary, circulations and that the contribution of the KCNQ channel 
opener in those circulations is variable. 
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5.  SUMMARY 
 
In this study we have tested the hypothesis that KCNQ channels are powerful targets for 
relaxation of small systemic and pulmonary arteries. We employed the PCR-method and small 
vessel myography on small skeletal muscle and pulmonary arteries from normotensive Wistar 
and hypertensive SHR rats. The following observations were made: 
 
1. Representatives of the KCNQ channel family are present in small systemic and 
pulmonary arteries. We have found mRNA expression for KCNQ1, KCNQ3, 
KCNQ4 and KCNQ5 channels now also in rat Gracilis arteries. Thus, they 
could be powerful targets for relaxation of these vessels.  
2. Preconstricted systemic and pulmonary arteries relax after the application of 
KCNQ channel opener. In particular, we showed strong relaxations of rat 
Gracilis and Intrapulmonary arteries by the novel KCNQ channel opener 
VRX0530727, VRX0621238 and VRX0621688. This relaxation was shown to 
be mediated by KCNQ channels (especially in the rat Gracilis artery). This 
finding shows that KCNQ channels are targets for the induction of vessel 
relaxation.  
3. The vasodilation induced by KCNQ channels opening does not depend on 
vessel type, but depends on the mechanism of vessel preconstriction. 
VRX0621238 and VRX0621688 relax vessels preconstricted by all studied 
agents, so they are the most potent vasodilators.  
4. The KCNQ channel opener VRX0530727, VRX0621238 and VRX0621688 as 
well as retigabine relax also arteries from hypertensive animals (Gracilis 
arteries from SHR rats). This additional finding demonstrates the premise that 
KCNQ channels may serve as therapeutic targets in the case of pathological 
hypertensive conditions.  
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Attachment  I 
 
PCR program 
 Command Time Process 
 CNTRL TUBE  
 LID105°  Warm up lid 
 WAIT AUTO  
1. T=45° 00:00:10  
2. Sound 5   
3. PAUSE "PRIMER MIX"  Add primers 
4. T=45° 00:30:00 Reverse Transcription 
5. Sound 5   
6. PAUSE “CONTROL”  Add control tubes, add primers 
7. T=94° 00:02:00 Denaturation of DNA 
8. T=94° 00:00:10 Denaturation of DNA 
9. T=56° 00:00:30 Annealing 
10. T=68° 00:01:10 Elongation 
11. GOTO 8 REP 9 (10 cycles) 
12. T=94° 00:00:10 Denaturation of DNA 
13. T=56° 00:00:30 Annealing 
14. T=68° 00:01:10 Elongation 
  0:05 s (ferment activity compensation) 
15. GOTO 12 REP 24 (25 cycles) 
16. T=68° 00:07:00 Elongation 
17. SOUND 5   
18. HOLD 4°  Cooling down 
 end   
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Attachment  II 
 
Solutions 
Solution I  
 Compounds 
 
Molecular weight,  
g/mol  
Final concentration,  
mM 
Amount  
for 1l 
 NaCl 58,40 120,00 7,008g   
 NaHCO3 84,01 26,00 2,184g   
 KCl 74,60 4,50 0,336g   
 NaH2PO4 x H2O  137,99     1,20 0,166g        
 MgSO4  120,40 1,00 0,120g 
 CaCl2                                  147,00 1,60 0,235g   
 Glucose 180,16 5,50 0,991g   
 (Na)EDTA (25mM stock solution) 372,24 0,03 1ml 
 (Na)Hepes 37°C     (0,5M) 238,30 5,00 10ml 
 
 
Solution I modified with 120 mM KCl 
 Compounds 
 
Molecular weight, 
 g/mol  
Final concentration,  
mM 
Amount  
for 1l 
 NaCl 58,40 4,50 0,263g 
 NaHCO3 84,01 26,00 2,184g 
 KCl 74,60 120,00 8,952g 
 NaH2PO4 x H2O   137,99     1,20 0,166g        
 MgSO4  120,40 1,00 0,120g 
 CaCl2                                  147,00 1,60 0,235g   
 Glucose 180,16 5,50 0,991g   
 (Na)EDTA (25mM stock solution) 372,24 0,03 1ml 
 (Na)Hepes 37°C     (0,5M) 238,30 5,00 10ml 
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Solution I without NaHCO3  
Compounds 
 
Molecular weight, 
 g/mol  
Final concentration,  
mM 
Amount  
for 1l 
 NaCl 58,40 146,00 8,5274g 
 NaHCO3 84,01 — — 
 KCl 74,60 4,50 0,336g   
 NaH2PO4 x H2O  137,99     1,20 0,166g        
 MgSO4  120,40 1,00 0,120g 
 CaCl2                                  147,00 1,60 0,235g   
 Glucose 180,16 5,50 0,991g   
 (Na)EDTA (25mM stock solution) 372,24 0,03 1ml 
 (Na)Hepes 37°C     (0,5M) 238,30 5,00 10ml 
 
 
Solution II 
Compounds 
 
Molecular weight, 
 g/mol  
Final concentration, 
 mM 
Amount  
for 1l 
 NaCl 58,40 145,00 8,468g 
 KCl 74,60 4,50 0,336g 
 NaH2PO4 x H2O     137,99     1,20 0,166g        
 MgSO4  120,40 1,00 0,120g 
 CaCl2                                  147,00 0,10 0,2ml 
 (Na)EDTA (25mM stock solution) 372,24 0,025 1ml 
 (Na)Hepes  4°C      (0,5M) 238,30 5,00 10ml 
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THESES 
 
KCNQ channels are a family of membrane potassium channels which are widely 
expressed in many organs. These channels play an important role in a variety of widespread 
diseases; their pharmacological modulators are used as effective medications in the nervous 
system. Although it was already shown that they play a very important role in excitable tissues, 
there are not much data about KCNQ channels in the vascular system.  
In our study we have tested the hypothesis that KCNQ channels are powerful targets for 
relaxation of small systemic and pulmonary arteries.  
We investigated the distribution of these channels in blood vessels. Their expression was 
studied in Gracilis arteries using the PCR-method. We investigated also the functional role of 
KCNQ channels in vessel relaxations induced by the novel KCNQ channel opener 
VRX0530727, VRX0621238 and VRX0621688 on isometric preparations of intact Gracilis and 
Intrapulmonary arteries using wire myography. We have tested our hypothesis on male 
normotensive Wistar and spontaneously hypertensive SHR rats.  
In rat Gracilis arteries we found mRNA expression for KCNQ1, KCNQ3, KCNQ4 and 
KCNQ5 channels. This artery, preconstricted with diverse agents (serotonin, phenylephrine or 
U-46619), showed different responses to KCNQ channel opener application, but VRX0621238 
and VRX0621688 always produced vessel relaxation.  
In serotonin-preconstricted Gracilis arteries relaxation by VRX0530727 was shown to be 
independent on the endothelium and sympathetic nerve endings. Vasodilation was mediated by 
KCNQ channels (proved in experiments with the specific KCNQ channel blocker XE-991). 
The novel KCNQ channel opener and retigabine dilate also arteries from hypertensive 
rats in the same way like in normotensive rats.  
KCNQ channel opener produce a relaxation in the pulmonary circulation resembling their 
effect on systemic arteries (we tested the effect of VRX0621238 and VRX0621688 on U-46619-
preconstricted Intrapulmonary arteries).  
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Our results confirm and extend already existing data on the role of KCNQ channels in 
small arteries reported by previously by other groups. 
Taking all our observations together we proved our hypothesis that KCNQ channels are 
powerful targets for relaxation of small systemic and pulmonary arteries. This conclusion is 
based on the following novel findings: 
1. Representatives of the KCNQ channel family are present in small non-visceral 
arteries.  
2. Preconstricted systemic and pulmonary arteries relax after the application of 
KCNQ channel opener. This relaxation is mediated by KCNQ channels.  
3. Novel KCNQ channel opener relax also arteries from hypertensive animals. 
This additional finding demonstrates the premise that KCNQ channels may 
serve as therapeutic targets in the case of pathological hypertensive conditions.  
 
 
 
 
 
 
 
